Authors: Gillian M Keating
Publish Date: 2013/04/26
Volume: 73, Issue: 6, Pages: 575-593
Abstract
Insulin degludec Tresiba® is an ultralongacting insulin analogue that is also available as a coformulation with rapidacting insulin aspart insulin degludec/insulin aspart Ryzodeg® Insulin degludec has a flat stable glucoselowering profile with a duration of action of 42 h and less withinpatient daytoday variability in glucoselowering effect than the longacting insulin analogue insulin glargine In clinical trials insulin degludec achieved similar glycaemic control to that seen with insulin glargine in patients with type 1 or 2 diabetes but with a lower risk of nocturnal hypoglycaemia In addition trials examining a flexible dosing regimen of insulin degludec in patients with type 1 or 2 diabetes show the potential for adjusting the injection time without compromising glycaemic control or safety A 200 U/mL formulation of insulin degludec is also available for use in patients who require large volumes of basal insulin Insulin degludec/insulin aspart was noninferior to the longacting insulin analogue insulin detemir in patients with type 1 diabetes and has the potential to reduce the number of daily injections Trial results also indicate that insulin degludec/insulin aspart may be an appropriate option for initiating insulin therapy in patients with type 2 diabetes inadequately controlled with oral antidiabetic drugs Subcutaneous insulin degludec was generally well tolerated in patients with type 1 or 2 diabetes In conclusion insulin degludec and insulin degludec/insulin aspart represent a useful advance in the treatment of type 1 or 2 diabetesThe manuscript was reviewed by K I Birkeland Oslo University Hospital and Faculty of Medicine Oslo Norway B Cariou Université de Nantes CHU de Nantes Hôpital Guillaume et RenéLaennec Nantes France E Franek Department of Internal Diseases Endocrinology and Diabetology Central Clinical Hospital MSWiA Warsaw Poland A B King Diabetes Care Center Salinas CA USA I Satman Division of Endocrinology and Metabolism Department of Internal Medicine Istanbul Faculty of Medicine Istanbul University Istanbul Turkey C J Tack Department of Internal Medicine Radboud University Nijmegen Medical Centre Nijmegen The NetherlandsThe preparation of this review was not supported by any external funding During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on this article Changes resulting from comments received were made by the author on the basis of scientific and editorial merit
Keywords: